Correlation of COVID-19 RT-PCR CT values and symptoms, duration and medication of patients.
Keywords:
Corona virus, Viral load, COVID-19, Ct-values, Co-morbidities, Severity, MedicationsAbstract
Coronaviruses (CoVs) belong to the subfamily Orthocoronavirinae in the family Coronaviridae, Order Nidovirales. There are 4 genera inside the subfamily Orthocoronavirinae, like Alphacoronavirus (α-CoV), Betacoronavirus (β-CoV), Gammacoronavirus (γ-CoV) and Deltacoronavirus (δ-CoV). The CoV genome is an enveloped, positive-sense, single-stranded RNA with a dimension various between 26 kb and 32 kb, the biggest genome of recognised RNA viruses.
Real Time Reverse Transcription Polymerase Chain Reaction (Real Time RT-PCR) is the gold widespread test for detection of SARS-CoV-2. This test allows early detection of viral genome in medical samples. A positive test permits the clinicians and public health experts to rapidly isolate the affected person and stop progression of the disease. The cycle threshold or Ct value of a RT-PCR response is the number of cycles at which fluorescence of the PCR product is detectable over and above the background signal. Theoretically, the Ct value is inversely proportional to the quantity of genetic material (RNA) in the beginning sample and decrease Ct values usually correlate with excessive viral load. It is being assumed with the aid of some researchers / clinicians that excessive viral load immediately correlates with elevated infectiousness and severity of disease. ICMR has mentioned the problem of correlating COVID-19 disease severity with Ct values and consequently figuring out on affected person management protocol, with a panel of esteemed laboratory experts. Real-time RT-PCR protocols for detecting SARS-CoV-2 in different countries. Three fluorescent indicators from FAM, ROX, and CY5 channels detected the viral replica DNA (cDNA). We selected the nucleocapsid protein gene N and the RNA-dependent RNA polymerase gene (RdRP) [also stated as Open Reading Frame 1ab (ORF1ab)]. Internal control helped to check for biases of the complete procedure. We used a positive control such as plasmids containing the whole SARS-CoV- two N gene in our study. In this study the reports that has been taken for the survey has selected these markers as control.
Downloads
References
Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, Lee M. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington state. JAMA. 2020; 323:1612. doi: 10.1001/jama.2020.4326.
BCCDC. COVID-19 vulnerable populations. British Columbia Centre for Disease Control. 2020. [Accessed April 18, 2020, http://www.bccdc.ca/health-info/diseases-conditions/covid-19/vulnerable-populations].
Boddington NL, Charlett A, Elgohari S, Walker JL, Mcdonald H, Byers C, et al. COVID-19 in Great Britain: epidemiological and clinical characteristics of the first few hundred (FF100) cases: a descriptive case series and case control analysis. medRxiv. 2020.05.18.20086157.
CDC Severe outcomes among patients with coronavirus disease 2019 (COVID-19) — United States, February 12–March 16, 2020. Centers for Disease Control and Prevention: MMWR. 2020;69(12):343–346. [PMC free article] [PubMed] [Google Scholar]
CDC. Coronavirus (COVID-19): symptoms of coronavirus. Centers for Disease Control and Prevention. 2020. [Accessed April 18, 2020, https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html].
Chang D, Mo G, Yuan X, Tao Y, Peng X, Wang FS, Xie L, Sharma L, dela Cruz CS, Qin E. Time kinetics of viral clearance and resolution of symptoms in novel coronavirus infection. AJRCCM. 2020;201:1150–1152. doi: 10.1164/rccm.202003-0524LE.
Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25(3)
Ebrahim Abbasi-Oshaghi, Fatemeh Mirzaei, Farhad Farahani, Iraj Khodadadi, Heidar Tayebinia Int J Surg. Diagnosis and treatment of coronavirus disease 2019 (COVID-19): Laboratory, PCR, and chest CT imaging findings.NCBI ,2020 Jul; 79: 143–153. 2020 May 15.
Franki R. Comorbidities the rule in New York’s COVID-19 deaths. Hospitalist. 2020; [Accessed June 1, 2020, https://www.the-hospitalist.org/hospitalist/article/220457/coronavirus-updates/comorbidities-rule-new-yorks-covid-19-deaths].
Garg S, Kim L, Whitaker M, O’Halloran A, Cummings C, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 — COVID-NET, 14 states, March 1–30, 2020. Centers for Disease Control and Prevention: MMWR. 2020;69(15):458–464. [PMC free article] [PubMed] [Google Scholar]
Huang C, Wang Y, Li X, Ren L, Zhao J, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi: 10.1016/S0140-6736(20)30183-5.
IAS. COVID-19 and HIV: what you need to know. The International AIDS Society. 2020. [Accessed April 20, 2020, https://www.iasociety.org/covid-19-hiv].
Jefferson T, Heneghan C. COVID-19: Clinical Utility of Cycle Threshold Values.The centre of evidence-based medicine, August 12, 2020.
Li B, Yang J, Zhao F, Zhi L, Wang X, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020;109:531–538. doi: 10.1007/s00392-020-01626-9. .
Li Q, Med M, Guan X, Wu P, Wang X, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. N Engl J Med. 2020; 382:1199–1207. doi: 10.1056/NEJMoa2001316.
Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr. 2020;109:1088–1095. doi: 10.1111/apa.15270.
Maragakis LL. Coronavirus symptoms: frequently asked questions. Johns Hopkins Medicine. 2020; [Accessed April 18, 2020, https://www.hopkinsmedicine.org/health/conditions-and-diseases/coronavirus/coronavirus-symptoms-frequently-asked-questions].
Meo SA, Alhowikan AM, Al-Khlaiwi T, Meo IM, Halepoto DM, et al. Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV. Eur Rev Med Pharmacol Sci. 2020;24(4):2012–2019. doi: 10.26355/eurrev_202002_20379. [PubMed] [CrossRef] [Google Scholar]
Pan, Y.; Zhang, D.; Yang, P.; Poon, L.L.M.; Wang, Q. Viral load of SARS-CoV-2 in clinical samples. Lancet Infect. Dis. 2020, 20, 411–412.
Paudel SS. A meta-analysis of 2019 novel coronavirus patient clinical characteristics and comorbidities. Research Square. 2020. 10.21203/rs.3.rs-21831/v1 [Accessed April 18, 2020, https://www.researchsquare.com/article/rs-21831/v1].
Perera, R.A.P.M.; Tso, E.; Tsang, O.T.Y.; Tsang, D.N.C.; Fung, K.; Leung, Y.W.Y.; Chin, A.W.H.; Chu, D.K.W.; Cheng, S.M.S.; Poon, L.L.M.; et al. SARS-CoV-2 virus culture and subgenomic RNA for respiratory specimens from patients with mild Coronavirus disease. Emerg. Infect. Dis. 2020, 26, 2701–2704.
Rabaan, A.A.; Tirupathi, R.;Sule, A.A; Aldali, J.; Mutair, A.A.; Alhumaid, S.; Muzaheed; Gupta, N.; Koritala, T.; Adhikari, R.; et al. Viral Dynamics and Real-Time RT-PCR Ct Values Correlation with Disease Severity in COVID-19. MDPI DIAGNOSTICS, 15 June 2021.
Scott J Bergman, PharmD, FCCP, FIDSA, BCPS, BCIDP; COVID-19 Treatment: Investigational Drugs and Other Therapies, The Medscape, Aug 05, 2021.
Shuva Das, Department of Microbiology, Chittagong Medical College, Chattogram, Bangladesh, Comorbidities of COVID-19 Patients with Low Cycle Threshold (Ct) Value of Nucleocapsid (N) Gene: An Application to Cluster-Based Logistic Model, Journal of Antivirals & Antiretrovirals,Feb 19, 2021.
van Kampen, J.J.A.; van de Vijver, D.A.M.C.; Fraaij, P.L.A.; Haagmans, B.L.; Lamers, M.M.; Okba, N.; van den Akker, J.P.C.; Endeman, H.; Gommers, D.A.M.P.J.; Cornelissen, J.J.; et al. Shedding of infectious virus in hospitalized patients with coronavirus disease-2019 (COVID-19): Duration and key determinants. medRxiv 2020.
Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID-19: Evidence from meta-analysis. Aging (Albany NY) 2020;12(7):6049–6057. doi: 10.18632/aging.103000.
Wang J, Hajizadeh N, Moore EE, McIntyre RC, Moore PK, et al. Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): a case series. J Thromb Haemost. 2020. 10.1111/jth.14828 [Accessed May 30, 2020, https://onlinelibrary.wiley.com/doi/full/10.1111/jth.14828]. [PMC free article] [PubMed]
WHO. Coronavirus COVID-19. World Health Organization. 2020. [Accessed April 29, 2020, https://covid19.who.int/].
WHO. Q&A on coronaviruses (COVID-19). World Health Organization. 2020. [Accessed April 18, 2020, https://www.who.int/news-room/q-a-detail/q-a-coronaviruses].
WHO. Q&A on COVID-19, HIV, and antiretrovirals. World Health Organization. 2020. [Accessed April 20, 2020, https://www.who.int/news-room/q-a-detail/q-a-on-covid-19-hiv-and-antiretrovirals].
W-Jie G, Liang W-H, He J-X, Zhong N-S. Cardiovascular comorbidity and its impact on patients with COVID-19. Eur Respir J. 2020;55:2001227. doi: 10.1183/13993003.01227-2020.
Wu C, Chen X, Cai Y, Xia J, Zhou Z, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020:e200994. 10.1001/jamainternmed.2020.0994 [Accessed April 20, 2020, https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2763184]. [PMC free article] [PubMed]
Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, Ji R, Wang H, Wang Y, Zhou Y. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis. 2020; S1201–9712(20):30136–30133. doi: 10.1016/j.ijid.2020.03.017.
Yousefzadegan S, Rezaei N. Case report: death due to novel coronavirus disease (COVID-19) in three brothers. Am J Trop Med Hyg. 2020;102:1203–1204. doi: 10.4269/ajtmh.20-0240.
Yu, J.; Kang, M.; Song, Y.; Xia, J.; Guo, Q.; Song, T.; He, J.; Yen, H.-L.; Peiris, M.; Wu, J. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. N. Engl. J. Med. 2020, 382, 1177–1179.
Zhao Q, Meng M, Kumar R, Wu Y, Huang J, et al. The impact of COPD and smoking history on the severity of COVID-19: A systemic review and meta-analysis. J Med Virol. 2020. 10.1002/jmv.25889 [Accessed May 30, 2020, https://pubmed.ncbi.nlm.nih.gov/32293753/]. [PMC free article] [PubMed]
Zhou F, Yu T, Du R, Fan G, Liu F, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062. doi: 10.1016/S0140-6736(20)30566-3.
Zhu L, She Z-G, Cheng X, Qin J-J, Zhang X-J, et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab. 2020; [Accessed May 30, 2020, https://www.sciencedirect.com/science/article/pii/S1550413120302382]. [PMC free article] [PubMed]
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Chandini Sayed
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license unless indicated otherwise in a credit line to the material. If the material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/ licenses/by/4.0/
